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A 75-year-old 70-kg male patient reports having worsening shortness of breath over
the past 2 years and now must stop to catch his breath after climbing 1 or 2 flights
of stairs. He has no angina pectoris. He has electrocardiographic evidence of an old
transmural anterior myocardial infarction. His comorbidities include hypertension
and hyperlipidemia. Examination reveals some leg edema and an S3 gallop, but
findings are otherwise unremarkable. The hemoglobin level is 150 g/L, and the
creatinine value is 120 mg/L. An echocardiogram shows a moderately dilated left
ventricle with anterior akinesia, mild mitral regurgitation, and an ejection fraction of
29%. Medications include angiotensin-converting enzyme inhibition, -blockade, a
diuretic, and a statin. The coronary angiogram shows triple-vessel disease with an
occluded left anterior descending artery and an occluded right coronary artery. Both
vessels fill retrogradely from a large circumflex artery that has one high-grade
stenosis in the obtuse marginal branch. All vessels are good targets for coronary
artery bypass grafting (CABG). A fluorodeoxyglucose positron emission tomo-
graphic scan viability study reveals a scar in parts of the anterior wall and the apex
and viability in the posterior wall and the septum.
This patient has ischemic heart failure with evidence of ventricular remodeling
after anterior infarction. Should he be treated medically, or should he be referred for
revascularization? If revascularization is chosen, should the ventricular shape be
corrected? Whatever your decision is, it may be the exact opposite from that of the
next physician.
The STICH (Surgical Treatment for IschemiC Heart failure) trial is the first
prospective randomized study in the history of coronary artery surgery to specifi-
cally assess the potential benefit of CABG in patients with heart failure and coronary
artery disease. The trial tests two hypotheses: (1) CABG combined with intensive
medical therapy improves long-term survival compared with medical therapy alone
and (2) surgical ventricular restoration (SVR) combined with CABG and medical
therapy improves survival free of hospitalization compared with CABG and medical
therapy without SVR. Contrary to expectations, there is an astonishing lack of
convincing evidence for either of these treatment modalities in this patient popula-
tion. Thus, a trial aimed at detecting the best treatment strategies in this continuously
growing patient population should be welcomed with high interest and support
among physicians in the field. The question “to STICH or not to STICH” should be
unanimously answered with “to STICH.” Yet the trial, professionally organized and
adequately funded, is experiencing difficulties in recruiting patients into strata in
which randomization into the medical treatment arm is possible. One may assume
that the reason for these recruitment difficulties is a treatment bias in the medical
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Lcommunity toward one treatment option. It is therefore
striking to realize that such a bias does not exist. As stated
previously, the chosen treatment arm for eligible patients
not randomized may differ completely from one center to
the next. We believe that the differences in clinical man-
agement decisions regarding the treatment of patients with
heart failure and coronary artery disease are based on per-
sonal physician perspectives and experiences and not on
firm clinical trial evidence. Thus, treatment decisions seem
to result from alternate interpretations of the question, “to
STICH or not to STICH?”
To treat patients such as the one we presented with a
greater degree of confidence, we must focus on addressing
3 basic questions.
1. Does CABG provide a survival benefit in patients with
coronary artery disease and heart failure?
2. What is the role of viability testing?
3. Which patients should be considered for SVR?
Coronary Revascularization in Heart Failure: Where
Is the evidence?
Our patient has graftable 3-vessel disease and good targets
for bypass grafting. Why should CABG not be performed
on him?
Nine trials have compared a strategy of initial CABG
with one of initial medical therapy, and 3 were of consid-
erable size in terms of patient enrollment, ie, the Coronary
Artery Surgery Study (CASS), the Veterans Affairs study,
and the European study. In all studies, the inclusion criteria
included the presence of stable angina and, therefore, are
unlikely to represent many patients with ischemic heart
failure. Yusuf and colleagues1 suggested in an overview of
these trials that CABG provides a survival benefit specifi-
cally in high-risk patients (ie, patients with triple-vessel
disease, left ventricular dysfunction, or both). However,
these conclusions have been seriously challenged.2 Specif-
ically, the analysis was questioned because the described
survival benefit was mainly due to the results of the Euro-
pean study.2,3 This study was the only trial that demon-
strated a sustained difference in cumulative mortality at 12
years, but its conclusions were critiqued because of excess
mortality in the medical treatment arm.3
Irrespective of this difference of opinion, it is important
to realize that none of these studies included the patient
population represented by our patient, ie, those with coro-
nary artery disease, severely compromised contractile func-
tion (ie, ejection fraction 35%), and symptoms of heart
failure rather than angina. In addition, only the CASS study
enrolled patients (n  780) with impaired left ventricular
function (ejection fraction 35%-50%)4 and assessed patients
with ejection fractions less than 35% (n  631).5 In both
reports, the outcomes were similar. CABG provided a sur-
vival benefit over initial medical therapy only if angina was
the leading symptom. The 10-year survival in the random-
The Journal of Thoraciized group was 80% for CABG, compared with 59% for
medical therapy (P  .01),4 and the 3-year survival in the
registry patients was 84% for CABG and 68% for medical
therapy (P  .05).5 However, when the leading symptom
was heart failure, the 10-year survival in the randomized
patients (72% and 76%)4 and the 3-year survival in the
registry patients (55% for both groups)5 was the same in the
2 treatment arms. On the basis of these results, both deci-
sions made for our patient may be considered correct. It is
therefore not surprising that 2 respected bodies of experts
have published opposing statements regarding the treatment
of this patient population. The CASS investigators write
that “patients with overt heart failure and the absence of
ischemic symptoms should not receive surgery,”5 whereas
the Heart Failure Guidelines of the Agency for Health Care
Policy and Research read, “It is not clear whether patients
whose predominant symptom is heart failure rather than
angina benefit from bypass surgery.”6 The latter opinion
more accurately reflects current opinion, because evidence
from CASS is now more than 20 years old, and optimum
medical and surgical therapies have changed considerably
over this time.
In addition to the scarcity of the available data, decision
making at present is further complicated because the ran-
domized and the retrospective cohort and observational
studies were performed before major advances had been
made in medical therapy for heart failure and before sub-
stantial improvements had been made in the safety of sur-
gical procedures performed in these high-risk patients. It is
interesting to note in this context that no randomized trial
comparing CABG versus medical therapy for with heart
failure has been performed in the last 10 years. Thus, a
prospective, randomized, multicenter trial (such as the
STICH trial) seems in order. However, this trial may no
longer be necessary because technological advances have
improved the capacity to image and diagnose the viability of
underperfused myocardial territories.
The Effect of Viability Testing on Decision Making
in Surgical Revascularization
Viability testing may be used to guide decision making in
patients with dysfunctional areas of their myocardium.7 Our
patient has proof of viability in most regions of the heart
(except in the anterior wall) in addition to his graftable
3-vessel disease. Thus, any type of revascularization should
allow the myocardium to recover its function. Is it therefore
acceptable to consider the patient for medical therapy or for
enrollment into the STICH trial? How can the potential
decision to treat the patient medically be defended?
Many studies have suggested that viability testing is
useful for decision making.7 However, one must be aware
that there are no prospective randomized trials assessing the
value of viability testing in patients with coronary artery
disease and contractile dysfunction. In addition, the studies
c and Cardiovascular Surgery ● Volume 129, Number 2 247




Lthat evaluated the effect of nuclear or positron emission
tomography viability imaging on intermediate or long-term
survival did not meet all or even most of the criteria put
forth by the Evidence-Based Medicine Working Group cri-
teria for the assessment of articles on therapeutic interven-
tions and prognosis.
Most of these studies show major methodologic deficien-
cies, including a broad mix of patients (ejection fraction,
24% to 50%; fraction of patients in New York Heart
Association class III-IV, 19% to 100%), small sample sizes
(from 35 to 137 per group), and no consideration of baseline
characteristics (more patients with angina were sent for
viability testing). These and more aspects have been re-
viewed and illustrated in detail elsewhere.8 Thus, many
patients included in the STICH population are not consid-
ered in these studies. The most important and limiting
methodologic weakness of previous studies is perhaps the
inherent selection bias. Treatment allocation to CABG or
medical therapy was made in most studies by physicians
who requested and, in some cases, interpreted the viability
tests. In addition, recent data with -blockers suggest that
functional improvement in viable myocardium is not depen-
dent necessarily on revascularization,9 thus adding further
evidence to the debate.
The current level of evidence regarding the use of via-
bility imaging is flawed and considered inadequate. There-
fore, a randomized clinical trial is mandated and necessary
to evaluate the usefulness of viability imaging in decision
making for or against revascularization. Another role of
viability testing may be to risk-stratify patients for CABG.
Although the simple demonstration of viable myocardium
may not predict a long-term survival benefit of CABG over
medical management, it may prove to be a predictor of
operative risk.
The Role of Surgical Ventricular Reconstruction for
Patients With Ischemic Heart Failure
Our patient has a further aspect of disease that may influ-
ence decision making: he shows evidence of a dilating (ie,
remodeling) ventricle and has an akinetic scar in the anterior
wall. Thus, he could be considered for revascularization
combined with surgical ventricular reconstruction.
Surgery on the left ventricle has been performed for
decades. Cooley and Hallman10 were the first to describe the
exclusion of a large left ventricular aneurysm by using a
patch. Although aneurysmectomy for large anterior or pos-
terior aneurysms with thinning of the wall has gained its
place in most cardiac surgical centers, controversy still
exists regarding whether similar techniques may also be
useful in treating patients with dilated ventricles and scarred
regions of the heart when the shape is not seriously distorted
by an aneurysm. Dor11 described an endoventricular patch
plasty for the reconstruction of a ventricle after myocardial
infarction in the early 1990s and went on in 1998 to dem-
248 The Journal of Thoracic and Cardiovascular Surgery ● Febronstrate that the results of this technique were just as good
in patients with akinetic regions in their ventricles as in
patients with dyskinetic—ie, aneurysmatic—regions. Al-
though the Dor procedure has been adopted by several
centers, it has not found general acceptance. Possible rea-
sons include a lack of evidence that demonstrates improve-
ments in morbidity or mortality with this technique in
patients with ischemic heart failure. A recent retrospective
database analysis assessed morbidity and mortality in pa-
tients with ischemic cardiomyopathy and dilated ventricles
who were referred for CABG. The outcome was signifi-
cantly better in the groups that received CABG plus ven-
tricular reconstruction (ie, a Dor procedure) compared with
patients who received CABG alone.12 Many other studies
have been published presenting mortality rates and long-
term survival after surgery on the left ventricle. None has
been conducted in a prospective, randomized manner with
an acceptable number of patients. The operative mortality in
these studies ranges between 0% and 20%, and the reported
5-year survival hovers around 70% for most studies, regard-
less of the study year and the reconstruction technique used.
Although this observation may suggest that the ventricular
repair technique has less of an effect on outcome, this is
confounded by the fact that patients with increasingly com-
plicated and high-risk disease have been undergoing oper-
ations in recent years.
The pathophysiologic processes that lead to the develop-
ment of ischemic heart failure have also changed over the
years, mainly because of major improvements in the treatment
of patients with acute myocardial infarctions and in medical
therapy. The implications of these changes for surgery on the
ventricle were the basis for an entire issue of Seminars in
Thoracic and Cardiovascular Surgery in 2001. They have
resulted in modifications to the Dor procedure with respect to
the size and shape of the reconstructed left ventricle. The
modified Dor procedure is also known as SVR.
Initial results with the SVR technique have recently been
published in a 3-year observational study by the RESTORE
group.13 The surgeons in this international group performed
this procedure on 662 patients who mainly had akinetic
defects in the anterior wall. The results have been promis-
ing, although any conclusions on the incremental efficacy of
SVR relative to CABG must be made with caution because
of the absence of a control group in the RESTORE registry.
The ejection fraction improved on average by 10% (29.7%
 11.3% to 40.0%  12.3%), and the patients had a
subjective benefit, as indicated by a significant improve-
ment in their New York Heart Association classification
(from III-IV to I-III). Hospital mortality was 7.7%, and
3-year survival was 89%. Despite these promising data, the
results were challenged by a report from Elefteriades and
colleagues,14 who demonstrated a similar improvement in
contractile function in a small and selected group of patients
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Lin whom isolated CABG surgery was performed. In addi-
tion to this controversy, several questions remain and will
not be answered unless they are investigated in a prospec-
tive randomized fashion. First, it is not clear whether SVR
provides a survival benefit over CABG alone (an answer
may arise from the second hypothesis of the STICH trial).
Second, it is unknown whether a reduction in the volume of
a dilated ventricle improves survival; and, finally, it is not
clear whether the reconstruction is actually able to revert or
stop the remodeling processes after the infarct. Thus, cur-
rent evidence does not allow us to satisfactorily answer the
question as to whether our patient should undergo SVR.
In summary, the appropriate treatment of patients with
ischemic heart failure is currently unknown, yet there is no
shortage of opinion regarding “optimum treatment.” This
balance of opinion highlights the need for sound clinical
evidence and underscores the very nature of clinical equi-
poise. The STICH trial is designed and powered to answer
fundamental clinical questions regarding the ischemic heart
failure population. Will coronary revascularization prolong
survival in patients with heart failure who have no symp-
toms of angina? How valuable are current imaging modal-
ities for predicting candidates for medical or surgical man-
agement? Is there a clinical benefit to SVR? In many
respects, the STICH trial will revisit a subset of patients
examined by CASS, but in the current era of optimum
medical and surgical therapy.
We thank Carole Cuerten for editorial assistance.
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